Relay Therapeutics: CFO Thomas Catinazzo sold 17,717 shares

What happened Thomas Catinazzo, chief financial officer, sold 17,717 shares of Relay Therapeutics common stock in open-market transactions on Oct 06, 2026 for total proceeds of $329,322. The filing reports 17,511 shares sold at a weighted average price of $18.58 for $325,354 and 206 shares sold at a weighted average price of $19.26 for $3,968.

Key details

• Transaction date(s) and price(s): Oct 06, 2026; 17,511 shares at weighted avg $18.58 (prices ranged $18.20 to $19.17); 206 shares at weighted avg $19.26 (prices ranged $19.20 to $19.27).
• Shares owned after the transaction: the filing notes 6,538 shares are underlying restricted stock units; the filing excerpt provided does not state a total post-transaction ownership figure.
• Relevant footnotes: the sales were effected pursuant to a Rule 10b5-1 trading plan adopted Oct 30, 2025 (F1); multiple-trade price ranges are disclosed and the filer offers to provide per-trade details on request (F2, F4); post-transaction ownership figure includes 6,538 shares underlying restricted stock units (F3).
• Filing date and report period: filed Oct 08, 2026 reporting transactions on Oct 06, 2026.

Why it may matter

• The filing shows open-market sales executed under a pre-established Rule 10b5-1 trading plan.
• This was a market sale (not an option exercise or a gift).
• A filing does not show why the insider traded or why the company acted.